Ligand-directed profiling: applications to target drug discovery in cancer

Bibliography

• Drews J. Stategic trends in the drug industry. Drug Discov Today 2003;8(9):411-20
   PubMed Web of Science ®Google Scholar
• Kubinyi H. Drug research: myths, hype and reality. Nat Rev Drug Discov 2003;2(8):665-8
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1(9):727-30
   PubMed Web of Science ®Google Scholar
• Williams M. Target validation. Curr Opin Pharmacol 2003;3(5):571-7
   PubMed Web of Science ®Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-6
   PubMed Web of Science ®Google Scholar
• Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov 2003;2(1):38-51
   PubMed Web of Science ®Google Scholar
• Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5(10):821-34
   PubMed Web of Science ®Google Scholar
• Kramer R, Cohen D. Functional genomics to new drug targets. Nat Rev Drug Discov 2004;3(11):965-72
   PubMed Web of Science ®Google Scholar
• Scherf U, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24(3):236-44
   PubMed Web of Science ®Google Scholar
• Jayapal M, Melendez AJ. DNA microarray technology for target identification and validation. Clin Exp Pharmacol Physiol 2006;33(5-6):496-503
   PubMed Web of Science ®Google Scholar
• Fingleton B. Molecular targets in metastasis: lessons from genomic approaches. Cancer Genomics Proteomics 2007;4(3):211-21
   PubMedGoogle Scholar
• Mayburd AL, Golovchikova I, Mulshine JL. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. Bioinformatics 2008;24(3):389-95
   PubMed Web of Science ®Google Scholar
• Dhamoon AS, Kohn EC, Azad NS. The ongoing evolution of proteomics in malignancy. Drug Discov Today 2007;12(17-18):700-8
   PubMed Web of Science ®Google Scholar
• Garcia-Foncillas J, Bandrés E, Zárate R, Remírez N. Proteomic analysis in cancer research: potential application in clinical use. Clin Transl Oncol 2006;8(4):250-61
   PubMedGoogle Scholar
• Serkova NJ, Spratlin JL, Eckhardt SG. NMR-based metabolomics: translational application and treatment of cancer. Curr Opin Mol Ther 2007;9(6):572-85
   PubMed Web of Science ®Google Scholar
• Wishart DS. Applications of metabolomics in drug discovery and development. Drugs R D 2008;9(5):307-22
   PubMed Web of Science ®Google Scholar
• Butcher EC. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 2005;4(6):461-7
   PubMed Web of Science ®Google Scholar
• Schrattenholz A, Soskic V. What does systems biology mean for drug development? Curr Med Chem 2008;15(15):1520-8
   PubMed Web of Science ®Google Scholar
• Terstappen GC, Schlüpen C, Raggiaschi R, Gaviraghi G. Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 2007;6(11):891-903
   PubMed Web of Science ®Google Scholar
• Hajitou A, Trepel M, Lilley CE, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006;125(2):385-98
   PubMed Web of Science ®Google Scholar
• Kolonin MG, Sun J, Do KA, et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006;20(7):979-81
   PubMed Web of Science ®Google Scholar
• Kolonin MG, Bover L, Sun J, et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 2006;66(1):34-40
   PubMed Web of Science ®Google Scholar
• Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004;10(6):625-32
   PubMed Web of Science ®Google Scholar
• Arap MA, Lahdenranta J, Mintz PJ, et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004;6(3):275-84
   PubMed Web of Science ®Google Scholar
• Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002;8(2):121-7
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 1998;10(6):560-5
   PubMedGoogle Scholar
• Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380(6572):364-6
   PubMed Web of Science ®Google Scholar
• Sato M, Arap W, Pasqualini R. Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology 2007;21(11):1346-52
   PubMed Web of Science ®Google Scholar
• Ozawa MG, Zurita AJ, Dias-Neto E, et al. Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems. Trends Cardiovasc Med 2008;18(4):126-32
   PubMed Web of Science ®Google Scholar
• Cardó-Vila M, Zurita AJ, Giordano RJ, et al. A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS One 2008;3(10):e3452
   PubMedGoogle Scholar
• Staquicini FI, Tandle A, Libutti SK, et al. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res 2008;68(20):8419-28
   PubMed Web of Science ®Google Scholar
• Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228(4705):1315-7
   PubMed Web of Science ®Google Scholar
• Smith GP, Scott JK. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 1993;217:228-57
   PubMed Web of Science ®Google Scholar
• Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433-55
   PubMed Web of Science ®Google Scholar
• Iannolo G, Minenkova O, Petruzzelli R, Cesareni G. Modifying filamentous phage capsid: limits in the size of the major capsid protein. J Mol Biol 1995;248(4):835-44
   PubMed Web of Science ®Google Scholar
• Malik P, Gowda LR, Langara A, et al. Role of capsid structure and membrane protein processing in determining the size and copy number of peptides displayed on the major coat protein of filamentous bacteriophage. J Mol Biol 1996;260(1):9-21
   PubMed Web of Science ®Google Scholar
• Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998;102(2):430-7
   PubMed Web of Science ®Google Scholar
• Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 1994;91(15):7129-33
   PubMed Web of Science ®Google Scholar
• Doorbar J, Winter G. Isolation of a peptide antagonist to the thrombin receptor using phage display. J Mol Biol 1994;244(4):361-9
   PubMed Web of Science ®Google Scholar
• Szardenings M, Törnroth S, Mutulis F, et al. Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1. J Biol Chem 1997;272(44):27943-8
   PubMed Web of Science ®Google Scholar
• Giordano RJ, Cardó-Vila M, Lahdenranta J, et al. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001;7(11):1249-53
   PubMed Web of Science ®Google Scholar
• Giordano RJ, Anobom CD, Cardó-Vila M, et al. Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. Chem Biol 2005;12(10):1075-783
   PubMed Web of Science ®Google Scholar
• Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000;19(7):1525-33
   PubMed Web of Science ®Google Scholar
• Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 1993;268(27):20205-10
   PubMed Web of Science ®Google Scholar
• Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994;124(3):373-80
   PubMed Web of Science ®Google Scholar
• Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81(14):1088-92
   PubMed Web of Science ®Google Scholar
• Chen BP, Li YS, Zhao Y, et al. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol Genomics 2001;7(1):55-63
   PubMed Web of Science ®Google Scholar
• St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289(5482):1197-202
   PubMed Web of Science ®Google Scholar
• Cahill DJ. Protein and antibody arrays and their medical applications. J Immunol Methods 2001;250(1-2):81-91
   PubMed Web of Science ®Google Scholar
• Angenendt P, Glökler J, Murphy D, et al. Toward optimized antibody microarrays: a comparison of current microarray support materials. Anal Biochem 2002;309(2):253-60
   PubMed Web of Science ®Google Scholar
• Trepel M, Grifman M, Weitzman MD, Pasqualini R. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum Gene Ther 2000;11(14):1971-81
   PubMed Web of Science ®Google Scholar
• Giordano RJ, Lahdenranta J, Zhen L, et al. Targeted induction of lung endothelial cell apoptosis causes emphysema-like changes in the mouse. J Biol Chem 2008;283(43):29447-60
   PubMed Web of Science ®Google Scholar
• Amundson SA, Do KT, Vinikoor LC, et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 2008;68(2):415-24
   PubMed Web of Science ®Google Scholar
• Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Nat Cancer Inst 1991;83(11):757-66
   PubMed Web of Science ®Google Scholar
• Okabe M, Szakács G, Reimers MA, et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 2008;7(9):3081-91
   PubMed Web of Science ®Google Scholar
• Shen L, Kondo Y, Ahmed S, et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 2007;67(23):11335-43
   PubMed Web of Science ®Google Scholar
• Whyte DB, Holbeck SL. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006;340(2):469-75
   PubMed Web of Science ®Google Scholar
• Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6(2):129-37
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10(8):789-99
   PubMed Web of Science ®Google Scholar
• Szantai-Kis C, Kövesdi I, Eros D, et al. Prediction oriented QSAR modelling of EGFR inhibition. Curr Med Chem 2006;13(3):277-87
   PubMed Web of Science ®Google Scholar
• Birnbaum A, Ready N. Gefitinib therapy for non-small cell lung cancer. Curr Treat Options Oncol 2005;6(1):75-81
   PubMedGoogle Scholar
• Cappuzzo F, Finocchiaro G, Metro G, et al. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol 2006;58(1):31-45
   PubMed Web of Science ®Google Scholar
• Feld R, Sridhar SS, Shepherd FA, et al. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol 2006;1(4):367-76
   PubMed Web of Science ®Google Scholar
• Ebi N, Semba H, Tokunaga SJ, et al. A Phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008;3(10):1166-71
   PubMed Web of Science ®Google Scholar
• Merlano M, Occelli M. Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag 2007;3(5):871-6
   PubMedGoogle Scholar
• Frieze DA, Mccune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 2006;40(2):241-50
   PubMed Web of Science ®Google Scholar
• Grisanti S, Amoroso V, Buglione M, et al. Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature. J Med Case Rep 2008;2(1):320
   Google Scholar
• Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008;19(2):99-113
   PubMed Web of Science ®Google Scholar
• Maiello E, Giuliani F, Gebbia V, et al. Cetuximab: clinical results in colorectal cancer. Ann Oncol 2007;18:8-10
   Google Scholar
• Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther 2007;7(2):243-56
   PubMed Web of Science ®Google Scholar
• Zurita AJ, Arap W, Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. J Control Release 2003;91(1-2):183-6
   PubMed Web of Science ®Google Scholar
• Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 2001;5(3):308-13
   PubMed Web of Science ®Google Scholar
• Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006;16(3):80-8
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Arap W, Mcdonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002;8(12):563-71
   PubMed Web of Science ®Google Scholar
• Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002;6(3):399-404
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15(6):542-6
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279(5349):377-80
   PubMed Web of Science ®Google Scholar
• Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 2008;112(7):2628-35
   PubMed Web of Science ®Google Scholar
• Hajitou A, Lev DC, Hannay JA, et al. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci USA 2008;105(11):4471-6
   PubMed Web of Science ®Google Scholar
• Pentz RD, Flamm AL, Pasqualini R, et al. Revisiting technical guidelines for research with terminal wean and brain-dead patients. Hasting Cent Rep 2003;33(1):20-6
   PubMed Web of Science ®Google Scholar
• Pentz RD, Cohen CB, Wicclair M, et al. Ethics guidelines for research with the recently dead. Nat Med 2005;11(11):1145-9
   PubMed Web of Science ®Google Scholar
• Zurita AJ, Troncoso P, Cardó-Vila M, et al. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 2004;64(2):435-9
   PubMed Web of Science ®Google Scholar
• Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J Biol Chem 1999;274(17):11593-8
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409(6822):860-921
   PubMed Web of Science ®Google Scholar
• Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291(5507):1304-51
   PubMed Web of Science ®Google Scholar
• Workman P. The impact of genomic and proteomic technologies on the development of new cancer drugs. Ann Oncol 2002;13(4):115-24
   PubMed Web of Science ®Google Scholar
• Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2001;2(2):4
   Google Scholar
• Knezevic V, Leethanakul C, Bichsel VE, et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 2001;1(10):1271-8
   PubMed Web of Science ®Google Scholar
• De Hoog CL, Mann M. Proteomics. Annu Rev Genomics Hum Genet 2004;5:267-93
   PubMed Web of Science ®Google Scholar
• Rajapakse JC, Duan KB, Yeo WK. Proteomic cancer classification with mass spectrometry data. Am J Pharmacogenomics 2005;5(5):281-92
   PubMedGoogle Scholar